ArticleBMC medical research methodology2026
PAtient-Centric epilepsy clinical trIal model For Improved health outcomes using Cannabidiol (PACIFIC study)-a methodology for developing patient-centred clinical trials in rare epilepsy syndromes.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials for rare epilepsies face substantial methodological and ethical challenges. Small and heterogeneous populations, coupled with limited validated outcome measures, often render traditional designs underpowered and unable to capture outcomes that are meaningful to patients and their families. Innovative approaches-such as decentralised, adaptive, and participatory designs-offer potential solutions but have rarely been systematically applied in this context.
methodsWe employed an exploratory three-phase sequential mixed-methods design to co-design a patient-centred clinical trial protocol for rare epilepsies in Australia. An expression-of-interest process recruited 40 participants, equally distributed across four advisory groups: patients, clinicians, researchers, and industry representatives. Phase 1 surveys collected demographic information, trial preferences, digital literacy, and perspectives on participation. Phase 2 comprised semi-structured interviews, analysed using reflexive thematic analysis, to identify themes relevant to trial design. In Phase 3, a consensus-driven process involving four structured online workshops with a multidisciplinary subcommittee translated these findings into a trial protocol recommendation.
resultsFour priorities emerged: (1) decentralised trial models to improve access and inclusion, particularly through home-based care; (2) embedding cultural safety and systems integration to support diversity; (3) prioritising outcomes beyond seizure reduction, including quality of life and patient-reported measures; and (4) improving communication and accessibility through digital innovation. These insights informed recommendations for an ethics-approved protocol emphasising inclusivity, feasibility, and real-world relevance.
conclusionsThis study demonstrates the feasibility of participatory co-design in developing rare epilepsy trial protocols. Embedding patient perspectives and adopting innovative methodologies can enhance scientific rigour, build trust, and strengthen the clinical and policy impact of rare disease research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.